Institution · Pharmacyclics (United States)

Most cited papers from Pharmacyclics (United States)

Pharmacyclics (United States)

What are the most cited papers from Pharmacyclics (United States)?

The most cited paper from Pharmacyclics (United States) is "Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia" (John C. Byrd et al., 2013), with 2,283 citations. Next come "Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma" (1,710) and "Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia" (1,649).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 199 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia John C. Byrd et al. · New England Journal of Medicine Open access	19 Jun 2013	2,283
2	Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma Michael Wang et al. · New England Journal of Medicine Open access	19 Jun 2013	1,710
3	Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia John C. Byrd et al. · New England Journal of Medicine Open access	31 May 2014	1,649
4	Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia Jan A. Burger et al. · New England Journal of Medicine Open access	6 Dec 2015	1,604
5	The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Lee A. Honigberg, Ashley M. Smith, Mint Sirisawad et al. · Proceedings of the National Academy of Sciences Open access	6 Jul 2010	1,553
6	Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Jennifer Ann Woyach et al. · New England Journal of Medicine Open access	28 May 2014	1,276
7	Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma Wyndham Hopkins Wilson et al. · Nature Medicine Open access	20 Jul 2015	1,130
8	Ibrutinib in Previously Treated Waldenström’s Macroglobulinemia Steven Peter Treon et al. · New England Journal of Medicine Open access	3 Apr 2015	943
9	Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Jason A. Dubovsky et al. · Blood Open access	25 Jul 2013	808
10	Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Sarah E. M. Herman, Amber L. Gordon, Erin K. Hertlein et al. · Blood Open access	22 Mar 2011	805
11	Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Laurie Helen Sehn, Alex Francisco Herrera, Christopher R. Flowers et al. · Journal of Clinical Oncology Open access	6 Nov 2019	785
12	Discovery of Selective Irreversible Inhibitors for Bruton’s Tyrosine Kinase Zhengying Pan, Heleen Scheerens, Shyr‐Jiann Li et al. · ChemMedChem	12 Dec 2006	682
13	Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib John C. Byrd, Richard R. Furman, Steven E. Coutre et al. · Blood Open access	20 Feb 2015	664
14	The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo Sabine Ponader, Shih‐Shih Chen, Joseph J. Buggy et al. · Blood Open access	17 Dec 2011	642
15	Lymphoma Remissions Caused by Anti-CD19 Chimeric Antigen Receptor T Cells Are Associated With High Serum Interleukin-15 Levels James N. Kochenderfer et al. · Journal of Clinical Oncology Open access	14 Mar 2017	569
16	The clinically active BTK inhibitor PCI-32765 targets B-cell receptor– and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia Martin F. M. de Rooij, Annemieke Kuil, Christian R. Geest et al. · Blood	26 Jan 2012	560
17	Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial Carol Moreno, Richard Greil, Fatih Demırkan et al. · The Lancet Oncology	3 Dec 2018	556
18	Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma Yibin Yang et al. · Cancer Cell Open access	Jun 2012	527
19	Ibrutinib for chronic graft-versus-host disease after failure of prior therapy David Bernard Miklos, Corey S. Cutler, Mukta Arora et al. · Blood Open access	18 Sep 2017	511
20	Bruton Tyrosine Kinase–Dependent Immune Cell Cross-talk Drives Pancreas Cancer Andrew J. Gunderson, Megan M. Kaneda, Takahiro Tsujikawa et al. · Cancer Discovery Open access	29 Dec 2015	495
21	Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma Talha Munir, Jennifer R. Brown, Susan Mary O'Brien et al. · American Journal of Hematology Open access	12 Sep 2019	480
22	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study Jan A. Burger, Paul M. Barr, Tadeusz Robak et al. · Leukemia Open access	18 Oct 2019	470
23	Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial Susan Mary O'Brien et al. · The Lancet Oncology Open access	9 Dec 2013	467
24	Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK Idit Sagiv-Barfi, Holbrook E K Kohrt, Debra Katherine Czerwinski et al. · Proceedings of the National Academy of Sciences Open access	17 Feb 2015	453
25	A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas Sriram Balasubramanian, Jason A. Ramos, Weigang Luo et al. · Leukemia Open access	7 Feb 2008	453
26	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results Michael Wang et al. · Blood Open access	9 Jun 2015	412
27	Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience Susan O’Brien, Richard R. Furman, Steven E. Coutre et al. · Blood Open access	2 Feb 2018	390
28	Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia Meletios Athanasios Dimopoulos, Alessandra Tedeschi, Judith Trotman et al. · New England Journal of Medicine Open access	Jun 2018	358
29	Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study Susan Mary O'Brien et al. · The Lancet Oncology	14 Sep 2016	341
30	Microbubble-enhanced ultrasound for vascular gene delivery Allan Lawrie, AF Brisken, Sheila Francis et al. · Gene Therapy	Dec 2000	341
31	Regression After Whole-Brain Radiation Therapy for Brain Metastases Correlates With Survival and Improved Neurocognitive Function Jing Li, Søren Møller Bentzen, Markus Frederic Renschler et al. · Journal of Clinical Oncology	30 Mar 2007	336
32	Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib Preetesh Jain, Michael J. Keating, William G. Wierda et al. · Blood Open access	9 Jan 2015	336
33	Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma Ariela Noy, Sven de Vos, Catherine Thiéblemont et al. · Blood Open access	7 Feb 2017	297
34	Relationship Between Neurocognitive Function and Quality of Life After Whole-Brain Radiotherapy in Patients With Brain Metastasis Jing Li, Søren Møller Bentzen, Jialiang Li et al. · International Journal of Radiation OncologyBiologyPhysics Open access	12 Apr 2008	296
35	Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia Paul M. Barr, Carolyn Owen, Tadeusz Robak et al. · Blood Advances Open access	4 Apr 2022	283
36	Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy Jennifer Ann Woyach et al. · Blood Open access	11 Jan 2014	281
37	Texaphyrins Jonathan L. Sessler, Richard Alan Miller · Biochemical Pharmacology	Apr 2000	278
38	Cell-Cycle Reprogramming for PI3K Inhibition Overrides a Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma David Chiron, Maurizio Di Liberto, Peter Martin et al. · Cancer Discovery Open access	Aug 2014	273
39	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials Jennifer R. Brown et al. · Haematologica Open access	27 Jul 2017	267
40	Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort Constantine Si Lun Tam, John Nathan Allan, Tanya Siddiqi et al. · Blood Open access	23 Feb 2022	252
41	Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab John C. Byrd et al. · Blood Open access	6 Mar 2019	248
42	Ibrutinib inhibits BCR and NF-κB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL Sarah E. M. Herman, Rashida Z. Mustafa, Jennifer Gyamfi et al. · Blood Open access	22 Mar 2014	247
43	The thioredoxin reductase/thioredoxin system: Novel redox targets for cancer therapy John E. Biaglow, Richard A. Miller · Cancer Biology & Therapy Open access	2005	245
44	Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL Jennifer R. Brown et al. · Leukemia Open access	8 Jun 2017	241
45	Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial Meletios Athanasios Dimopoulos et al. · The Lancet Oncology	9 Dec 2016	241
46	HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination Shanthi Adimoolam, Mint Sirisawad, Jun Chen et al. · Proceedings of the National Academy of Sciences Open access	27 Nov 2007	240
47	The emerging role of reactive oxygen species in cancer therapy Markus Frederic Renschler · European Journal of Cancer	25 Jun 2004	240
48	The Bruton tyrosine kinase inhibitor PCI-32765 ameliorates autoimmune arthritis by inhibition of multiple effector cells Betty Y Chang, Min Mei Huang, Michelle R. Francesco et al. · Arthritis Research & Therapy Open access	13 Jul 2011	234
49	Ibrutinib Plus Venetoclax for First-Line Treatment of Chronic Lymphocytic Leukemia: Primary Analysis Results From the Minimal Residual Disease Cohort of the Randomized Phase II CAPTIVATE Study William G. Wierda et al. · Journal of Clinical Oncology Open access	7 Oct 2021	233
50	Isoform-specific histone deacetylase inhibitors: The next step? Sriram Balasubramanian, Erik J. Verner, Joseph J. Buggy · Cancer Letters	17 Mar 2009	222

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.